Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Roche, ACT Genomics, and Sygnis

NEW YORK (360Dx) – Roche said this week that it has commenced a cash tender offer for all outstanding shares of common stock of Foundation Medicine at a price of $137 per share. The offer follows Roche's announcement last month that it plans to acquire all the remaining outstanding Foundation shares that it did not already own. Unless extended, the tender offer period will expire at midnight, US Eastern time, on July 30. Following the tender offer, Roche will acquire all remaining Foundation shares at the same price through a second-step merger. The closing of the transaction is expected in the second half of this year.

ACT Genomics said this week that it has signed a memorandum of understanding with Bumrungrad International Hospital (BIH) to offer genomic diagnostic services to patients in Thailand. ACT utilizes NGS technology to determine the mutational landscape of patients' tumors and analyzes the data with a proprietary bioinformatics pipeline and database in order to provide clinicians and cancer patients with help making personalized treatment decisions. Through this deal, ACT and BIH said they are aiming to provide cancer patients in Thailand with precision therapy options.

During its annual general meeting this week, Sygnis changed its name to Expedeon. The name change aligns the corporate face of the company with its customer facing brands, including those in the genomics, proteomics, and immunology markets, the firm's CEO and CSO, Heikki Lanckriet, said in a statement.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.

Filed under